LeukemiaNCT05425992
Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families
An observational study of Leukemia and Non Hodgkin Lymphoma, run by University of Colorado, Denver at 1 site in United States.
Trial summary
This study will seek to improve communication with Spanish speaking families and patients with Cancer and Blood Disorders. Read more about this study
- Who is it for?
- Ages Up to 22 years
- Conditions the study is for
- Leukemia, Non Hodgkin Lymphoma
- What is being tested?
- Interview
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 17 Mar 2022to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 22 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Patients eligible for enrollment are identified from EPIC electronic medical record with notification for newly diagnosed families of Spanish language preference.
Who may be able to join
- 0 to 22 years of age
- Diagnosis of leukemia or non-Hodgkin lymphoma
- Spanish as preferred language for patient, parent or guardian
- Received or receiving care at the Center for Cancer and Blood Disorders (CCBD)
Who cannot join
- Patients without oncologic diagnosis
- Patients with parents whose language preference is English
- Patients who received care solely outside of the CCBD
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Children's Hospital Colorado
Aurora, Colorado, 80045
Wendy Moore, 1-720-777-6353, wendy.moore@childrenscolorado.org
Ashley Rogers
About this study
Official title: Improving Communication With and Building a Stronger Medical Home Among Spanish-speaking Families in the Center for Cancer and Blood Disorders
This study will seek to improve communication with Spanish speaking families and patients with Cancer and Blood Disorders.
Read the detailed description
The Principal Investigator seeks to improve communication with Spanish speaking families with the following goals: 1) to increase patient and family sense of inclusion in the medical community, 2) to increase patient and family medical knowledge and understanding, 3) to improve patient adherence with critical medical regimens, and ultimately, 4) to increase equality of comprehensive medical care delivery across the continuum of care including physical and psychosocial domains.
- Conditions
- Leukemia, Non Hodgkin Lymphoma
- Being tested
- Interview
- Keywords
- Spanish-speaking
- Medical subject headings
- Leukemia, Lymphoma, Non-Hodgkin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InterviewOther
Patient/parent dyads expressing interest will be interviewed by a bilingual Spanish certified provider via televideo with as needed interpreter support. Interviews will be audio recorded for review and translation purposes and then will be destroyed. Interview format will be supportive and information seeking only with reassurance that purpose is for care improvement and that all answers will be evaluated without association to patient name. Interviews will then be translated and reviewed by the PI for themes regarding perceived clinic successes and perceived clinic barriers in communication or care.
| Study group | Role | What they receive |
|---|---|---|
| Patients treated in CCBD | Patients who are currently receiving therapy at the Center for Cancer and Blood Disorders Receives: Other: Interview |
What is being measured
The primary outcome is the main question the study is designed to answer.
Determine a baseline level of Spanish speaking patient satisfaction of care
Understand the patient experience using qualitative interview of Spanish speaking patients and families Determine satisfaction based on open-ended question with unsatisfied to satisfied as markers.
Measured: 12 months
Determine a baseline level of Spanish Speaking family satisfaction of care
Understand the patient experience using qualitative interview of Spanish speaking patients and families Determine satisfaction based on open-ended question with unsatisfied to satisfied as markers.
Measured: 12 months
Determine effects of language barrier on Spanish speaking patient needs
Understand the patient experience using qualitative interview of Spanish speaking patients and families.
Determine satisfaction based on open-ended question to determine a list or pattern of common patient needs.
Measured: 12 months
Determine the effect of language barrier on barriers to patient care
Understand the patient experience using qualitative interview of Spanish speaking patients and families.
Determine satisfaction based on open-ended question to determine a list or pattern of common barriers to patient care.
Measured: 12 months
Effect of language barrier on efficiency of access to care
Understand the patient experience using qualitative interview of Spanish speaking patients and families.
Determine satisfaction based on open-ended question to determine how quickly patient was able to receive care.
Measured: 12 months
Secondary outcomes (6)
Determine patient interest in home telemedicine support program
Open-ended questions will be used to determine level of interest in a telemedicine support program.
Measured: 12 months
Determine patient interest in home telemedicine support program after discharge
Open-ended questions will be used to determine level of interest in a telemedicine support program to be used after discharge from hospital.
Measured: 12 months
Determine Spanish speaking patient interest in telemedical check-ins during intensive phases of therapy
Open-ended questions will be used to determine level of interest in a telemedical support during treatment.
Measured: 12 months
Determine Spanish speaking patient interest in medication assistance during intensive phases of therapy
Open-ended questions will be used to determine level of interest in a telemedical medication support during therapy.
Measured: 12 months
Determine Spanish speaking patient interest in medical check-ins during maintenance
Open-ended questions will be used to determine level of interest in a telemedical check-ins during maintenance.
Measured: 12 months
Determine Spanish speaking patient interest in medication assistance during maintenance
Open-ended questions will be used to determine level of interest in a telemedical medication assistance during maintenance.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jun 2022
- Study start17 Mar 2022
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LeukemiaStudies of the same condition, open and under way.
- More trials run by University of Colorado, DenverThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Colorado, Denver
- Sponsor type
- University, hospital or other
- Collaborators
- Children's Hospital Colorado
- Responsible party
- Sponsor
- Investigators
- Ashley Rogers, Principal investigator, Children's Hospital Colorado
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05425992
- Sponsor's protocol ID
- 21-4238.cc
- Other IDs
- NCI-2022-04061
- Status last verified
- Feb 2026
- First submitted
- 15 Jun 2022
- Last updated
- 5 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving Communication With and Building a Stronger Medical Home Among Spanish-speaking Families in the Center for Cancer and Blood Disorders
- ClinicalTrials.gov ID
- NCT05425992
- Acronym / sponsor ID
- 21-4238.cc
- Conditions
- Leukemia, Non Hodgkin Lymphoma
- Keywords
- Spanish-speaking
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- University of Colorado, DenverUniversity, hospital or other
- Collaborators
- Children's Hospital Colorado
- Study start
- 17 Mar 2022 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 21 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will seek to improve communication with Spanish speaking families and patients with Cancer and Blood Disorders.
Detailed description
The Principal Investigator seeks to improve communication with Spanish speaking families with the following goals: 1) to increase patient and family sense of inclusion in the medical community, 2) to increase patient and family medical knowledge and understanding, 3) to improve patient adherence with critical medical regimens, and ultimately, 4) to increase equality of comprehensive medical care delivery across the continuum of care including physical and psychosocial domains.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients treated in CCBD | – | Other: InterviewPatients who are currently receiving therapy at the Center for Cancer and Blood Disorders |
Who may qualify
- Ages
- Up to 22 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Patients eligible for enrollment are identified from EPIC electronic medical record with notification for newly diagnosed families of Spanish language preference.
Key inclusion criteria (4 listed)
- 0 to 22 years of age
- Diagnosis of leukemia or non-Hodgkin lymphoma
- Spanish as preferred language for patient, parent or guardian
- Received or receiving care at the Center for Cancer and Blood Disorders (CCBD)
Key exclusion criteria (3 listed)
- Patients without oncologic diagnosis
- Patients with parents whose language preference is English
- Patients who received care solely outside of the CCBD
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| InterviewPatient/parent dyads expressing interest will be interviewed by a bilingual Spanish certified provider via televideo with as needed interpreter support. Interviews will be audio recorded for review and translation purposes and then will be destroyed. Interview format will be supportive and information seeking only with reassurance that purpose is for care improvement and that all answers will be evaluated without association to patient name. Interviews will then be translated and reviewed by the PI for themes regarding perceived clinic successes and perceived clinic barriers in communication or care. | Other | Patients treated in CCBD |
Primary outcome
Determine a baseline level of Spanish speaking patient satisfaction of care
Time frame: 12 months
Understand the patient experience using qualitative interview of Spanish speaking patients and families Determine satisfaction based on open-ended question with unsatisfied to satisfied as markers.
Determine a baseline level of Spanish Speaking family satisfaction of care
Time frame: 12 months
Understand the patient experience using qualitative interview of Spanish speaking patients and families Determine satisfaction based on open-ended question with unsatisfied to satisfied as markers.
Determine effects of language barrier on Spanish speaking patient needs
Time frame: 12 months
Understand the patient experience using qualitative interview of Spanish speaking patients and families. Determine satisfaction based on open-ended question to determine a list or pattern of common patient needs.
Determine the effect of language barrier on barriers to patient care
Time frame: 12 months
Understand the patient experience using qualitative interview of Spanish speaking patients and families. Determine satisfaction based on open-ended question to determine a list or pattern of common barriers to patient care.
Effect of language barrier on efficiency of access to care
Time frame: 12 months
Understand the patient experience using qualitative interview of Spanish speaking patients and families. Determine satisfaction based on open-ended question to determine how quickly patient was able to receive care.
6 secondary outcomes
Determine patient interest in home telemedicine support program
Time frame: 12 months
Determine patient interest in home telemedicine support program after discharge
Time frame: 12 months
Determine Spanish speaking patient interest in telemedical check-ins during intensive phases of therapy
Time frame: 12 months
Determine Spanish speaking patient interest in medication assistance during intensive phases of therapy
Time frame: 12 months
Determine Spanish speaking patient interest in medical check-ins during maintenance
Time frame: 12 months
Determine Spanish speaking patient interest in medication assistance during maintenance
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Leukemia
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
AML (Acute Myeloid Leukemia)
RecruitingPhase 1
Vididencel in CML-CP Patients With MRD
CML (Chronic Myelogenous Leukemia)
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ashley Rogers principal investigator
Children's Hospital Colorado
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Leukemia and Non Hodgkin Lymphoma, run by University of Colorado, Denver at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Wendy Moore (1-720-777-6353, wendy.moore@childrenscolorado.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Determine a baseline level of Spanish speaking patient satisfaction of care (time frame: 12 months). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.